TMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team
|
|
- Tobias Goodwin
- 6 years ago
- Views:
Transcription
1 TMF Reference Model Topline results of 2014 TMF Survey #4 August 2014 Fran Ross TMF Survey Sub-team
2 Trial Master File (TMF) Survey Background TMF Survey purpose: industry-wide, gather insight into quality, cost and effectiveness drivers of TMF management, including: Knowledge and use of TMF Reference Model Changes in TMF management and processes Impacts of electronic TMF and e-investigator Site File Insight into health authority inspection trends Data for 2014 Survey #4 was collected in May to July of 2014 Previous surveys were conducted in 2010, 2012, and 2013 A survey team will regroup for work on the fifth TMF Survey in 1Q2015. Your feedback, insight and participation are enthusiastically welcomed. The TMF Survey sub-team and the Trial Master File Reference Model (TMF RM) initiative is a subgroup of the Document and Records Management SIAC of the Drug Information Association 2014 TMF Survey 2
3 Trial Master File (TMF) Survey Background TMF Survey purpose: industry-wide, gather insight into quality, cost and effectiveness drivers of TMF management, including: Knowledge and use of TMF Reference Model TMF management pain points Paper vs electronic TMF Data for the 2014 was collected from May to July 2014 This TMF Survey has been conducted as an initiative of the TMF Reference Model (TMF RM) and is performed annually. The TMF RM committee and leadership operate in coordination with the EDM Reference Model as initiatives of the Document and Records Management (DRM) Community in the DIA 2014 TMF Survey 3
4 Report Sections Respondent Demographics TMF / etmf Insights TMF Metrics TMF Reference Model Use Inspection Trends Electronic Investigator Site File (eisf) 2014 TMF Survey 4
5 RESPONDENT DEMOGRAPHICS 5
6 Respondent Organization Type 231 Evaluable Responses Sponsor organizations majority respondents (57%) Your organization type: 10% 6% 4% Sponsor Site 9% 13% 2% 57% CRO Consultant Vendor 2014 TMF Survey 6
7 Respondent Location Where are you located? 1% 5% 62% 32% Africa Asia Pacific Europe Latin America USA / Canada 0% 2014 TMF Survey 7
8 Trial Outsourcing Profile What percentage of current Phase II/III trials are fully outsourced to CROs? (select closest percentage) 30% 4% 18% 100% fully out sourced 76 99% 51 75% 25% 26 50% 0 25% 9% Not applicable 14% 2014 TMF Survey 8
9 Active Trials Indicate the number of active trials at your organization 3% 23% 13% 9% 10% 13% 29% 1 to 4 5 to to to to to TMF Survey 9
10 TMF / etmf INSIGHTS 10
11 TMF SOP Adherence Does your organization have and follow a TMF SOP? 1% 0% 1% 11% Yes, followed consistently Yes, followed inconsistently Yes, not followed 26% No, in development 61% No, no plans for SOP Not required 2014 TMF Survey 11
12 Paper TMF or Electronic TMF (etmf) What format is your TMF file of record? 1% All Inspectable TMF in paper 33% All Inspectable etmf 58% Combination of inspectable paper and inspectable etmf 8% Other (please comment) 2014 TMF Survey 12
13 etmf Status What is the status of your organization's etmf? 14.5% 3.9% 3.3% We currently use etmf Evaluating 44.1% Actively Planning 15.1% Actively Building/Implementing Not Considering 19.1% Not Applicable / Unknown 2014 TMF Survey 13
14 etmf Duration How long has your etmf been in production? 2% 15% 19% 34% 15% 15% Less than 1 Year 1 Year 2 3 Years 4 5 years 6 or more years Other (please specify) 2014 TMF Survey 14
15 More Than One etmf? Do you use more than one etmf system? 3% No 22% Yes we have multiple etmfs 14% 61% Yes ours and our partner's (e.g. CRO) etmfs Other (please specify) 2014 TMF Survey 15
16 Issues When Using More Than One etmf System Which of the following issues do you encounter using more than one etmf system? (select all that apply) 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% None Increased effort for reconcilation Difficulty establishing file of record User Confusion Increased cost burden Increased complication with submission processing 2014 TMF Survey 16
17 etmf Archive Process What is the etmf post trial "archive" process"? 3% 14% 28% No archive process, remains in system Electronic archive, remains in system 7% Electronic archive, moved to another system Stored on external media 17% Printed hard copy 31% Other (please specify) 2014 TMF Survey 17
18 TMF METRICS 18
19 TMF Metrics Program Do you have a TMF metrics program in place? 4% Yes, we have a metrics program. 24% 24% No, but we are evaluating the need for a program. 11% 37% No, but we are implementing a metrics program. No, we are not planning a metrics program Other (please specify) 2014 TMF Survey 19
20 TMF Metrics Program Measurements What do you measure in your TMF Metrics Program? (select all that apply) 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Completeness of TMF Document Classification Quality (filed accurately / assigned to correct document type) Document Metadata Quality (correctness of metadata) Image Quality (e.g. missing/extra pages, skewing, etc.) System usage (etmf) (e.g., daily or weekly logins) Timeliness of processing TMF documents Volume of documents processed Other (please specify) 2014 TMF Survey 20
21 TMF Metrics - Cost Do you measure TMF costs? 8% 5% 36% Yes No N/A Other (please specify) 51% 2014 TMF Survey 21
22 TMF Metrics Cost Efficiency Opinion Do you believe your TMF is cost efficient? 18% 9% 21% 24% Very cost efficient Somewhat Neutral Somewhat inefficient Very inefficient 28% 2014 TMF Survey 22
23 TMF REFERENCE MODEL USE 23
24 TMF Reference Model Awareness Are you aware of the TMF Reference Model? 5% Yes No 95% 2014 TMF Survey 24
25 TMF Reference Model Use Is your organization using the TMF Reference Model? 0% 11% Yes No 25% 64% Don't Know Not Applicable (Vendor, Health Authority, Consultant, Other) 2014 TMF Survey 25
26 TMF Reference Model for paper or etmf? My organization is using the Model for... 1% 6% 11% 43% 39% Paper TMFs only etmfs only Both paper and etmfs Don't know Other (please specify) 2014 TMF Survey 26
27 TMF Reference Model Use in New and Ongoing Trials My organization is using the Model in... (select all that apply) 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% New TMFs Ongoing studies with restructured TMF Ongoing studies with documents added to/removed from TMF Closed TMFs 2014 TMF Survey 27
28 TMF Reference Model Adoption Practices Has your organization adopted the Model as is, without any change? 12% 27% Yes, adopted as is No, adapted with changes Other (please specify) 61% 2014 TMF Survey 28
29 TMF Reference Model Adoption Methods In adopting the Model, my organization is 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Adding artifacts Condensing artifacts Branching artifacts into sub-artifacts Changing the RM numbering system Restructuring the zones Other changes (please specify) 2014 TMF Survey 29
30 TMF Reference Model Adoption Impacts 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Updating/planning to change SOPs Creating/updating guidance or best practice documents Mapping TMF structure to model Changing active TMFs to reflect model Other (please specify) 2014 TMF Survey 30
31 INSPECTION TRENDS 31
32 Inspector Opinion TMF Modality Do you have a preference for clinical trial documentation / TMF inspection modality? 29% 14% 14% etmf Paper TMF Doesn't matter Depends (comment) 43% 2014 TMF Survey 32
33 Inspector Opinion etmf Inspection Use Are you / would you be comfortable completing an inspection in an etmf? 43% 57% Yes No Depends (comment) 0% 2014 TMF Survey 33
34 Inspector Opinion TMF Reference Model Do you find the TMF Reference Model supports activities in clinical trial inspections 29% Yes 71% 0% No Not aware of the TMF Reference Model 2014 TMF Survey 34
35 Sponsor Inspection History 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Have you had regulatory agency / health authority inspections of your etmf? (select all that apply) No etmf Inspections US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 35
36 Sponsor Remote Inspection History Have you yet had a remote (off premise) inspection by any regulatory agency / health authority? 21% 24% Yes No Unknown 55% 2014 TMF Survey 36
37 Sponsor Inspection History Paper Requests 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Has any inspector refused to use etmf and required paper print out of TMF? No refusal US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 37
38 Sponsor Inspection History etmf Resistance 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Has any inspector refused to use paper and required access to etmf? No refusal US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 38
39 Sponsor Opinion - Inspection Preparation Impact Has the etmf helped ease burdens of audits / inspections? 10% 24% 66% Yes No Unknown 2014 TMF Survey 39
40 Sponsor Opinion - etmf Inspection Impact Have auditors or inspectors found the etmf easier to inspect using your etmf software? 34% 31% Yes No 7% 28% We do not allow inspector direct access to the etmf Unknown 2014 TMF Survey 40
41 Sponsor Opinion etmf Impact Unannounced Inspections Has the etmf proved a benefit in allowing you to support unannounced inspections? 31% 55% Yes No Unknown 14% 2014 TMF Survey 41
42 ELECTRONIC INVESTIGATOR SITE FILE (e-isf) 42
43 etmf Externalization Does your etmf externalize content to clinical trial sites (e.g. Investigator Portal)? 31% 8% 20% We currently externalize content Evaluating Actively Planning 18% 12% 11% Actively Building/Implementing Not Considering Not Applicable / Unknown 2014 TMF Survey 43
44 eisf Usage Are electronic Investigator Site Files (eisf) being used in your trials? 13% Yes No 87% 2014 TMF Survey 44
45 Percentage of Trials with eisf What percent of your trials have an electronic Investigator Site File (eisf)? 21% 10% 37% 0 25% 26 50% 51 75% % 32% 2014 TMF Survey 45
46 eisf Excluded Content 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Which of the following documents, if any, are NOT stored in the eisf (select all that apply) Subject Signed Informed Consent Signed Financial Disclosures Signed Contracts Unblinded Subject Identification Log Payment/Finance Documents 2014 TMF Survey 46
47 eisf Archive Process What is the eisf post trial "archive" process? 5% 5% 16% 5% 32% No archive process, remains in system Electronic archive, remains in system Electronic archive, moved to another system Stored on external media Printed hard copy 37% Other (please specify) 2014 TMF Survey 47
48 eisf Technology Control Is the eisf the site's technology or sponsor / CRO's technology? 0% 21% Site Sponsor / CRO Other (please specify) 79% 2014 TMF Survey 48
49 Barriers to eisf uptake If no eisf, why not? (choose all that apply) 50.0% 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% Technical Constraints Regulatory concerns/barriers Legal concerns/barriers Local country concerns Site refusal Financial barriers Not considered Other (please specify) 2014 TMF Survey 49
50 TMF Reference Model Participate! Contact co-chairs to join TMF Ref Model Team: Karen Roy, Lisa Mulcahy, To stay up to date on TMF Ref Model team progress and active discussions, read the blog: Join Linked In group TMF Reference Model The TMF Ref Model and overview information is free and available here TMF Survey 50
51 TMF 2014 Survey team THANK YOU! Shah Ashraf Kathie Clark Fran Ross Steve Scribner Thanks to Chris McSpiritt for preliminary results deck support! 2014 TMF Survey 51
Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal
Karen Roy Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal Paul Fenton Co-chair of the TMF Reference Model
More information11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf
11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf Penelope K. Manasco, M.D. CEO MANA RBM pmanasco@manarbm.com etmfs are rapidly replacing paper trial master
More informationVeeva 2017 Unified Clinical Operations Survey
PRELIMINARY FINDINGS Veeva 2017 Unified Clinical Operations Survey The Veeva 2017 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment
More informationVeeva 2015 Paperless TMF Survey: Annual Report
Veeva 2015 Paperless TMF Survey: Annual Report REMOVING PAPER FROM THE PROCESS The Veeva 2015 Paperless TMF Survey explores the life sciences industry s progress toward paperless clinical trials by gathering
More informationetmf From Libraries of Paper to Electronic Filing Cabinets to Databases
ClinTech 2014 etmf From Libraries of Paper to Electronic Filing Cabinets to Databases 12 March 2014 Kelley Robinson TMF Process Analyst Why an etmf Platform? A dynamic solution to enable active contribution,
More informationVeeva 2016 Paperless TMF Survey
Veeva 2016 Paperless TMF Survey The Veeva 2016 Paperless TMF Survey explores the life sciences industry s progress in streamlining clinical trials and unifying clinical operations. It represents the experiences
More informationIntralinks Studyspace : Electronic Investigator-Controlled Site File (eisf)
Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Introduction Intralinks Studyspace: Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace eisf solution is
More informationConstructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer
Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationPoints to Consider When Developing a TMF (Trial Master File) Strategy
PHLEXGLOBAL WHITE PAPER Points to Consider When Developing a TMF (Trial Master File) Strategy Presented By: Karen Redding Global Business Development Director Phlexglobal Ltd. kredding@phlexglobal.com
More informationWelcome Steering Committee Update Reminder to Vote! TMF RM Community ICH Update Implementation and User guide Change Control Board Exchange mechanism
19 March 2018 Welcome Steering Committee Update Reminder to Vote! TMF RM Community ICH Update Implementation and User guide Change Control Board Exchange mechanism Other Subgroup activity update MHRA Data
More informationVeeva 2015 Paperless TMF Survey: Annual CRO Report
Veeva 2015 Paperless TMF Survey: Annual CRO Report The Veeva 2015 Paperless TMF Survey: Annual CRO Report explores the progress made by contract research organizations (CROs) toward paperless clinical
More informationTop Challenges with Late Stage Trial Master Files
Top Challenges with Late Stage Trial Master Files The transition from a paper to an electronic Trial Master File (TMF) system is a significant task. In many cases, some pharma and biotech firms (sponsors)
More informationTrial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1
Trial Master File Reference Model Project Charter Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Prepared by The Exchange Mechanism Standard Subgroup of the TMF Reference
More information2016 Paperless TMF Survey: CRO Report Michael Burton Director, Vault Clinical. Copyright 2017 Veeva Systems Inc., all rights reserved veeva.
2016 Paperless TMF Survey: CRO Report Michael Burton Director, Vault Clinical Third Annual Veeva Paperless TMF Survey: CRO Report Understand the impact of etmf adoption among CROs on TMF processes Examine
More informationGCP Regulatory Inspection Readiness. March 29, 2018
GCP Regulatory Inspection Readiness March 29, 2018 GCP Regulatory Inspection Readiness Panelists: Kathy Goldstein, PharmD, Sr. Director, R&D Quality and Compliance, Alexion Pharmaceuticals, Inc. David
More informationPhlexglobal Whitepaper
Phlexglobal Whitepaper Dashboard Metrics: The Solution to Document Risk-Based Monitoring Presented By: Claire Jarmey-Swan Product Development Manager Email: CJarmey-Swan@phlexglobal.com Phlexglobal Inc.
More informationFULL TABLE OF CONTENTS AND CHARTS & GRAPHICS
TRIAL MASTER FILE MANAGEMENT UPHOLD DOCUMENTATION PROCESSES TO SAFEGUARD GOOD CLINICAL PRACTICES FULL TABLE OF CONTENTS AND CHARTS & GRAPHICS 68 T.W. Alexander Dr. P.O. Box 13628 Research Triangle Park,
More informationBuilding an etmf on Documentum. Sanofi-Pasteur s experience
Building an etmf on Documentum Béatrice Neyret Director and Global Head, Clinical Documentation Sanofi-Pasteur Momentum Berlin, November 2, 2011 1 Agenda Introduction What is the TMF? The TMF at Sanofi-Pasteur
More informationTrends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference
Trends in pharmacovigilance inspection deviations 8th Scandinavian SARQA/DKG Quality Assurance Conference Thorsten Jørgensen, PV Auditor, LEO Global Quality 1 Disclaimer This presentation does not represent
More informationWhat you missed at the 3 rd Trial Master File Summit January 28-29, Alexandria, VA.
What you missed at the 3 rd Trial Master File Summit January 28-29, 2014 - Alexandria, VA www.exlevents.com/tmf Why an etmf Platform? A dynamic solution to enable active contribution, organization, maintenance
More informationRegulatory requirements and registration process of Generic Drugs in China
13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationData Integrity in Clinical Trials the Sponsor Perspective
Data Integrity in Clinical Trials the Sponsor Perspective Maximilian Stroebe, GSK Vaccines Three differences to Commercial Manufacturing Long process chains Source Data, Clinical Sites and Outsourcing
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationPlease note that these comments and the identity of the sender will be published unless a specific justified objection is received.
11.07.2017 Submission of comments on 'Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials'
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationImplementation Guide 14-Mar-2018
Implementation Guide 14-Mar-2018 This document is freely distributable and is based on the opinions of the TMF Reference Model User Guide and Implementation Subgroup. Identification Authors Name Organization
More informationAgile-ing Your TMF Using Software Development Methodology to Maintain Quality in the TMF
Agile-ing Your TMF Using Software Development Methodology to Maintain Quality in the TMF Presented January 16, 2018 7 th Trial Master File Summit Orlando, FL Terri Baker Expert Services Wingspan, a QuintilesIMS
More informationPhlexEview: Transforming Costly Paper Processes into Value Driven Compliance
PHLEXGLOBAL WHITE PAPER PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance Presented By: Karen Redding Global Business Development Director Phlexglobal, Ltd. kredding@phlexglobal.com
More informationEXECUTIVE SUMMARY 4TH TRIAL MASTER FILE SUMMIT. Join the Conversation Group: Good Clinical Records Management.
EXECUTIVE SUMMARY 4TH TRIAL MASTER FILE SUMMIT Join the Conversation Group: Good Clinical Records Management CONTENTS INTRODUCTION 3 PRESENTATIONS 4 RESOURCES FOR INFORMATION AND DISCUSSION 11 INTRODUCTION
More informationYour Complete Quality Solution Provider for the Life Science Industry
Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,
More informationAdvance Information Management through etmf and CTMS Convergence. Troy Deck Wingspan Technology
Advance Information Management through etmf and CTMS Convergence Troy Deck Wingspan Technology Agenda Purpose of and Intersections between etmf and CTMS Benefits of Integration Challenges of Integration
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationREQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA. March 3, 2017
REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA March 3, 2017 OVERVIEW Recovered plasma requirements: EU fractionator point of view Collection of plasma Quality and audit requirements Safety
More informationDATA INTEGRITY IN CLINICAL RESEARCH. Singapore Clinical Research Professional (CRP) Forum 25 August 2017
DATA INTEGRITY IN CLINICAL RESEARCH Singapore Clinical Research Professional (CRP) Forum 25 August 2017 Welcome! David W. Fryrear Senior Director R&D Quality Assurance Joined AbbVie in 2013 Responsibilities
More informationIndex of Standard Operating Procedures for all research Sponsored by the UHL
University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the March Please note that with effect from 2015, all SOPs and Appendices use the same
More informationAMI MQP Market & Regulatory Analysis. Kyle Cayabyab Jameel Galloway Matt Hammond Meagan Ward
AMI MQP Market & Regulatory Analysis Kyle Cayabyab Jameel Galloway Matt Hammond Meagan Ward Overview Percentage PERCENT ARRHYTHMIA CASES THAT ARE AF 70 60 50 40 30 20 10 0 Percent Arrhythmia Cases that
More informationINVESTIGATOR SITE FILES SUMMIT
From the creators of the TMF series INVESTIGATOR SITE FILES SUMMIT Best Practices for Ensuring Compliant, Timely and Quality ISF Management for CROs, Sponsors and Sites SEPTEMBER 19-20, 2016 WYNDHAM BOSTON
More informationVeeva 2018 Unified Clinical Operations Survey
PRELIMINARY FINDINGS Veeva 2018 Unified Clinical Operations Survey The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment
More information2013/2014 Report
2013/2014 Staying@Work Report U.S. Executive Summary Introduction U.S. organizations have long looked to health and productivity programs as one way to keep workers healthier and stem the tide of higher
More informationFDA Perspective on International Clinical Trials
FDA Perspective on International Clinical Trials Kassa Ayalew, M.D., M.P.H. Division of Clinical Compliance Evaluation (DCCE) Office of Scientific Investigations (OSI) Center for Drug Evaluation and Research
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationInternational Supply Chain: How are we handling globalisation? GCP oversight
International Supply Chain: How are we handling globalisation? GCP oversight Susana Almeida, PhD Senior Director, European Operations Inflamax Research (Canada) patients quality value sustainability partnership
More information3M Pulp and Paper Sourcing Policy Progress Report
3M Pulp and Paper Sourcing Policy Progress Report November 2017 3M Pulp and Paper Sourcing Policy Progress Report November 2017 In March 2015, 3M revised our Pulp and Paper Sourcing Policy, which formalizes
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationUnderstanding True etmf Requirements:
www.arisglobal.com A White Paper Presented By ArisGlobal Understanding True etmf Requirements: Meeting Today s Expectations of Industry and Regulatory Agencies Dr. Mathias Poensgen Product Manager, Clinical
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version
More informationGLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals
GLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals For more information, contact: Stewart Eisenhart Senior Regulatory Analyst marketing@emergogroup.com
More informationMDSAP Me M dical D e D vice S i S ngle Audit Program
MDSAP Medical Device Single Audit Program Gary Minks VP, Quality & Regulatory Affairs TÜV SÜD America Inc. gminks@tuvam.com Revision: 2013(09(29 TÜV SÜD America 13(04(29 Slide 1 IMDRF International Medical
More informationCLINICAL TRIALS INSPECTION READINESS SUMMIT. Trial Master Files. Inspection Trends. Metrics Analysis. Partner Oversight
5th CLINICAL TRIALS INSPECTION READINESS Ensure Inspection Readiness Through Improved Early Preparation Standards, Organized Documentation and Continuous Vigilance from All Stakeholders August 8-9, 2016
More informationTitle: Audit and Inspection of the IEC. SOP Code: SOP/24/V1.0. Effective date: 03/05/2013
Page 1 of 6 Title: Effective date: 03/05/2013 1 Page 2 of 6 Table of Contents No. Content Page No. 1 Purpose 3 2 Scope 3 3 Responsibility 3 4 Flow chart 3 5 Detailed instructions 3 5.1 Call for an Audit
More informationDocument Title: Handling of drug alerts and recalls of IMPs
Document Title: Handling of drug alerts and recalls of IMPs Document Number: SOP074 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager,
More informationDrug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018
Drug Registration in BRICS countries: Opportunities and Challenges Judith ter Horst 1 November 2018 Once a drug reaches Phase1, it s a good idea to start discussions with global regulatory authorities
More informationGLOBAL TRENDS SURVEY REPORT
GLOBAL TRENDS SURVEY REPORT + OVERVIEW Clinical trials have become increasingly global in scope. Some countries require testing of drugs in a country before they can be approved for sale in that country.
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationData Integrity Why is it important? DADM Conference - 22 August 2017
Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of
More informationLake County School District. Quality Assurance & Improvement Program. Internal Self-Assessment for. The Internal Audit Department
Lake County School District Quality Assurance & Improvement Program Internal Self-Assessment for The Internal Audit Department Fiscal Year 2017 2018 Completed By: Thomas A. Mock, CIA Date: January 31,
More informationDigital Pathology World Market Report 2017
Research Proposal Publishing October 2018 Market Reports Digital Pathology World Market Report 2017 2017 Edition This is a research proposal for a new Market Report on Digital Pathology, to be published
More informationWHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific
WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical
More informationAbout The CMO Survey. Mission. Survey operation. Sponsoring organizations
About The CMO Survey Mission - To collect and disseminate the opinions of top marketers in order to predict the future of markets, track marketing excellence, and improve the value of marketing in firms
More informationReflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials
1 2 3 4 5 6 7 1 February 2013 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)
More informationList of Figures and Tables
1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 Worldwide Pharmaceutical Market Estimated Size, 2001-2008 Major World Markets Population Size and Sales Growth
More informationWhat you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA
What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA For a complete overview download the 2013 Executive Summary Notice of Inspection US FDA European Regulatory
More informationMedical Device Solution
Medical Device Solution How to Achieve FDA 21 Part 820 Compliance With Polarion Europe, Middle-East, Africa: Polarion Software GmbH Lautlinger Weg 3 70567 Stuttgart, GERMANY Tel +49 711 489 9969-0 Fax
More informationThe Case for ICH E6(R2) Compliance Assessment
The Case for ICH E6(R2) Compliance Assessment The Clinical landscape has become increasingly challenging due to growing demand from regulators and the public for more and better clinical research results.
More informationIndex of Standard Operating Procedures for all research Sponsored by the UHL
University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the October Please note that with effect from 2015, all SOPs and Appendices use the same
More informationList of Figures and Tables
1.01 p. 50 1.02 p. 50 1.03 p. 51 1.04 p. 51 1.05 p. 52 1.06 p. 52 1.07 p. 53 1.08 p. 53 1.09 p. 54 1.10 p. 54 1.11 p. 55 1.12 p. 55 1.13 p. 56 1.14 p. 56 1.15 p. 57 1.16 p. 57 1.17 p. 58 1.18 p. 58 1.19
More informationEU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved.
EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved. Background & Requirements - See Webinars BSI Website Copyright 2015 BSI.
More informationCase Study: Implementing an e-validation Solution within a BioPharma Company
Case Study: Implementing an e-validation Solution within a BioPharma Company Index Company Background Business Drivers Alternatives Identified Solution Justification Implementation Strategy Solution Implementation
More informationTimeliness of TMF Document Submission: from Finalized to Filed
Timeliness of TMF Document Submission: from Finalized to Filed Vittoria Sparacio, MSc CBI s etmf Forum Hyatt at de Bellevue Philadelphia 18 November 2014 Finally my turn to say... I know I am standing
More informationFRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?
FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationRisk-Based Monitoring Update Volume IV
Risk-Based Monitoring Update Volume IV 1. Introduction TransCelerate s Risk-Based Monitoring (RBM) initiative continues to produce tangible outputs during the first half of 2015. The purpose of RBM Update
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationHarmonizing Manufacturing across Multiple Sites and Regions
Harmonizing Manufacturing across Multiple Sites and Regions ISCT North America Regional Meeting Philadelphia, Pennsylvania Byron T. McAllister B.T. McALLISTER ASSOCIATES, INC. Tuesday, 10 September 2013
More informationImpact of MRCT after ICH E17 fully implement -Industry perspective-
Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation
More informationTRIAL MASTER FILE TMF EUROPEAN SUMMIT OCTOBER, 2014 HILTON LONDON KENSINGTON
3RD ANNUAL THE ONLY CONFERENCE IN EUROPE COMPLETELY DEDICATED TO TRIAL MASTER FILES! EUROPEAN TRIAL MASTER FILE SUMMIT Maintaining a Compliant Electronic and Paper TMF for Audits and Inspections 20 21
More informationClinical Trial Disclosure: Current US Situation
Clinical Trial Disclosure: Current US Situation 1 Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationDocument Title: Annual Progress Reports (APRs) Document Number: 056
Document Title: Annual Progress Reports (APRs) Document Number: 056 Version: 1 Ratified by: Committee Date ratified: 30/11/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationDIA Document & Records Management SIAC
DIA Document & Records Management SIAC EDM Reference Model Clinical Domain John Aitken, PhD Director, Regulatory Operations Gilead Sciences Inc Points to Cover Clinical Domain In scope: CTD clinical documents
More informationWelcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services
Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available
More informationCDISC Customer Requirements Analyses
Data Model Customer Requirements Analyses Copyright 2003 About The Clinical Data Interchange Standards Consortium () is an open, multidisciplinary, non-profit organization committed to the development
More informationRevision of Chapter 7 Contract Manufacture and Analysis
Revision of Chapter 7 Contract Manufacture and Analysis GMP & Market Compliance Information Day, 14-10-2010 Catherine Neary Inspector Date Insert on Master Slide Slide 1 Overview Purpose of revision to
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationConsiderations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc.
Considerations for Global Development of Orphan Drugs Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. 1 Disclosures Shareholder No Grant/research support No Consultant
More informationQuality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)
Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! Today, many companies operate
More informationSection. Clinical CRO Future Industry Leadership & Performance Benchmarking. October, Syndicated Report
Section Clinical CRO Future Industry Leadership & Performance Benchmarking Syndicated Report October, 2015 1 Table of Contents I. Study Background and Methodology 3 II. Study Respondent Demographics 6
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationMedical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.
Medical Device Single Audit Program (MDSAP) International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan
More informationHow To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014
How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014 Topics Why early clinical development in Asia-Pacific? Access to patient populations
More informationWhy Industry Collaborations Matter TransCelerate BioPharma, Inc.
Why Industry Collaborations Matter TransCelerate BioPharma, Inc. Jackie Kent Eli Lilly & Co. Shared Investigator Platform Initiative Leader, TransCelerate BioPharma Inc. Introduced by: Carlo Maccarrone
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationGMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd
GMP Compliance George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd June 2017 Overview GMP Definition and Regulation Our Philosophy and Strategy for Compliance Project Lifecycle Deliverables Master
More informationState of the Clinical Trials Industry
State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A
More information